D-Wave Quantum Stock Rallies After Q3 Results

D-Wave Quantum stock rose after a Dec. 2 Q3 beat and $54.6M warrant redemption, prompting analyst upgrades and raising questions about dilution risk.

December 05, 2025·3 min read
View all news articles
Flat filled vector server module symbolizing D-Wave Quantum stock rally tempered by dilution and liquidity shift.

KEY TAKEAWAYS

  • Q3 revenue about $3.7 million and loss per share near $0.05, both beating consensus.
  • Warrant redemption generated about $54.6 million and issued roughly 6.9 million new shares, altering dilution.
  • Following the report, commercial adoption accelerated while the company remained unprofitable with limited operating leverage.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

D-Wave Quantum stock rose after the company said in a press release on Dec. 2, 2025, that it beat quarterly expectations and completed a warrant redemption, highlighting accelerating commercial adoption even as the firm remains unprofitable and faces rising competition.

Earnings Beat, Liquidity, and Analyst Upgrades

D-Wave reported Q3 2025 revenue of about $3.7 million and a loss per share near $0.05, both ahead of consensus estimates of roughly $3.0 million and a loss of $0.07 a share. The company said its trailing-twelve-month revenue grew about 156%, with a gross profit margin near 82.8%, reflecting rapid top-line expansion from a small base and the high margins typical of cloud and service offerings.

The company completed the redemption of all outstanding public warrants, generating approximately $54.6 million in cash proceeds through the exercise of about 4.75 million warrants and issuing roughly 6.9 million new common shares. This capital-structure change affects near-term dilution and liquidity.

Equity research responded with raised price targets. Benchmark lifted its target from $20 to $35, and Cantor Fitzgerald raised its target from $20 to $40, both maintaining Buy ratings and citing the company’s commercialization progress and strategic position in quantum computing.

Commercial Progress and Competitive Landscape

D-Wave positions itself as the first commercial supplier of quantum computers and the only firm building both quantum annealing systems and gate-model processors. This dual-track roadmap aims to serve near-term optimization workloads and longer-term universal applications.

The company reports customers shifting from proofs-of-concept to multi-year, production-grade workloads in logistics, manufacturing, financial services, and defense. Elevated renewal rates and recurring usage suggest growing integration into enterprise workflows.

Its annealing platform targets combinatorial and routing optimization problems suited to early commercial needs, while debate continues over whether annealing or gate-based architectures will dominate the market. Experts estimate fully functional, large-scale quantum machines remain five to ten years away, leaving specialized and hybrid systems like D-Wave’s as the likeliest near-term sources of commercial value.

D-Wave’s stock has advanced roughly 168%–206% this year, making it one of the top-performing quantum computing stocks in 2025. Recently, the stock slipped below its 50-day moving average while holding above its 200-day average, a technical pattern traders watch as a sign of short-term weakness within a longer-term uptrend.

Despite commercial momentum, D-Wave remains unprofitable. Coverage highlights limited operating leverage as costs rise faster than revenue, posing a risk to converting growth into sustainable profits.

The company created a U.S. Government Solutions business unit, led by Jack Sears Jr., to pursue federal procurement in logistics, transportation, and national-security applications. It highlighted deployments such as an Advantage2 annealer at a defense contractor in Alabama.

Meanwhile, industry reports note rapid advances abroad. China’s Hanyuan-1 system has begun commercial sales and export orders, raising geopolitical stakes for U.S. suppliers and influencing procurement priorities.

Analysts’ upgraded targets and the strengthened capital structure give D-Wave more runway to advance its commercial agenda. Whether it can convert high-margin revenue growth into durable profits while fending off intensifying competition will determine if the company sustains its recent rally.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

SoFi Stock Offering Sparks After-Hours Drop

SoFi Stock Offering Sparks After-Hours Drop

SoFi stock offering triggered investor concern after the company priced 54,545,454 shares at $27.50 for $1.5 billion and shares slid over 6% after hours.

Rubrik Q3 Earnings Show Profit Turnaround

Rubrik Q3 Earnings Show Profit Turnaround

Rubrik Q3 earnings beat expectations with near fifty percent revenue growth and its first positive non-GAAP operating income, shifting trader positioning.

Samsara Q3 Earnings Show Profitability, Slowing Guidance

Samsara Q3 Earnings Show Profitability, Slowing Guidance

Samsara Q3 earnings showed the company's first GAAP profit on Dec. 4, 2025, with 29% ARR growth but guidance slowed and muted near-term stock reaction.

HPE Earnings Hurt by Server Revenue Slide

HPE Earnings Hurt by Server Revenue Slide

HPE earnings reported growth but warned that delayed AI server deals and server revenue decline pressured guidance and knocked shares lower after-hours.

Ulta Beauty Q3 Earnings Beat, Company Raises Outlook

Ulta Beauty Q3 Earnings Beat, Company Raises Outlook

Ulta Beauty Q3 earnings topped forecasts and management raised full-year sales to $12.3 billion, sending shares higher and signaling resilience in beauty.

Hims & Hers Canada Expansion Targets Weight Loss

Hims & Hers Canada Expansion Targets Weight Loss

Hims & Hers Canada expansion follows an all-cash Livewell acquisition and sets up a GLP weight-loss program timed to expected generic semaglutide.